贝莫苏拜单抗的全国发货,将为广大ES-SCLC患者提供新的用药选择,至于其销售定价,更多是为医保谈判做准备吧。
参考:
1.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20240509140023172.html2.Han Y, Wang J, Sun T, et al. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer[J]. Signal Transduction and Targeted Therapy, 2023, 8(1): 429.3.https://mp.weixin.qq.com/s/k8J5oip4LVRRt_qzmN6KXQ4.https://www.cttq.com/